drugset / Trial / NCT03361228
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and antitumor activity of INCB001158 plus epacadostat, with or without pembrolizumab, in participants with advanced or metastatic solid tumors.
Timeline
- Start
- 2018-03-01
- Primary completion
- 2019-03-30
- Completion
- 2019-03-30
Outcome
Outcome not reported
Stopped: “Study was terminated early based on emerging data with epacadostat and pembrolizumab.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epacadostat | Small molecule | — | Oral |
| Subject | NUMIDARGISTAT | Small molecule | — | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |